No recent analyst price targets found for APLIF.
Latest News for APLIF
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”),…
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for APLIF.
Senate Trading
No Senate trades found for APLIF.
U.S. House Trading
No House trades found for APLIF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.